You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that during independent laboratory testing, its assay had 100 percent sensitivity for detecting HIV-1 p24, anti-HIV-1, and anti-HIV-2 in positive samples.
The app would provide step-by-step guidance on how to perform the test and provide positive COVID-19 data to public health officials.
Clinical Enterprises received EUAs for two molecular tests, including one that uses self-collected nasal swab samples, while Qorvo's test detects viral antigens.
GenScript's test measures the presence of neutralizing antibodies for SARS-CoV-2 and has received EUA from the US Food and Drug Administration.
The firm won't have to pay off its unsecured convertible notes until 2026 to investors, including Patrick Soon-Shiong's Nant Capital.
The UK-based firm aims to begin evaluating kidney disease biomarkers in expanded clinical validation studies later this year.
The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.
Core revenues were up 10 percent organically, while COVID-19 testing contributed $535 million to revenues in Q1 2021.
The multi-center study is evaluating the use of Cofactor's OncoPrism test in predicting head and neck cancer patients' response to immunotherapy with other tumor types to follow.
The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.